Contact Information Available for logged-in reporters only Newswise A non-invasive test that includes detection of the genetic abnormalities related to cancer could significantly improve the effectiveness of colon cancer screening, according to research published by a team of scientists including David Ransohoff, MD, professor of medicine at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center member. The large-scale, cross-sectional study was published online today in The New England Journal of Medicine. The study compared two different types of tests used for screening colorectal cancer: a non-invasive, multitarget stool test that includes DNA markers related to colon cancer along with a test that detects stool blood, versus a commercial fecal immunochemical test (FIT). While the FIT test detects hidden blood in the stool, a potential signal for cancer, the multitarget test also includes genetic mutations in the stool that are related to cancer. In the study of nearly 10,000 participants, the DNA test detected 92 percent of colon cancer, significantly more cancers compared to the 72 percent for the FIT test in asymptomatic participants at average risk for colorectal cancer. The results from this study could impact screening rates, which remain frustratingly low in the U.S. despite the … Continue reading →

PUBLIC RELEASE DATE: 19-Mar-2014 Contact: Katy Jones katy_jones@unc.edu 919-962-3405 University of North Carolina Health Care A non-invasive test that includes detection of the genetic abnormalities related to cancer could significantly improve the effectiveness of colon cancer screening, according to research published by a team of scientists including David Ransohoff, MD, professor of medicine at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center member. The large-scale, cross-sectional study was published online today in The New England Journal of Medicine. The study compared two different types of tests used for screening colorectal cancer: a non-invasive, multitarget stool test that includes DNA markers related to colon cancer along with a test that detects stool blood, versus a commercial fecal immunochemical test (FIT). While the FIT test detects hidden blood in the stool, a potential signal for cancer, the multitarget test also includes genetic mutations in the stool that are related to cancer. In the study of nearly 10,000 participants, the DNA test detected 92 percent of colon cancer, significantly more cancers compared to the 72 percent for the FIT test in asymptomatic participants at average risk for colorectal cancer. The results from this study could impact screening rates, which remain … Continue reading →

Contact Information Available for logged-in reporters only Newswise NEW YORK (March 19, 2014) New research shows an alternative DNA test offers clinically relevant genetic information to identify why a miscarriage may have occurred years earlier. Researchers were able to identify chromosomal variants and abnormalities in nearly 50 percent of the samples. This first-of-its-kind study was conducted by researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University. The results were published in the March issue of Reproductive Biology and Endocrinology. The technique used in this study, called rescue karyotyping, allows physicians to obtain important genetic information from tissue that had not been tested at the time of the miscarriage. As part of standard hospital protocol, tissue from miscarriages is embedded in paraffin for archival use and the karyotyping test is performed on DNA extracted from this tissue. In this retrospective study of 20 samples from 17 women, genetic testing was successfully performed on 16 samples that had been archived for as long as four years. Of those samples, eight showed chromosomal variants and abnormalities. This is an important alternative when conventional karyotyping is not available or cannot be used for a specific sample. Given the … Continue reading →

Autism By: Stem Cell Therapy Center EMCELL … Continue reading →

Henderson, Nevada (PRWEB) March 18, 2014 According to Dr. Srinubabu Gedela, the Managing Director of OMICS Publishing Group , the main aim of the Cell Science-2014 is to broadening the scope of the research in this field. The OMICS Group Conferences 4th world congress on Cell Science & Stem Cell Research deliberates on the broader areas of Evolution of cancer, Tumorogenesis, Recombinant DNA technology, Cancer cell development and signaling pathway, Genetic engineering and Gene therapy, Tumor suppressor genes, Tissue Engineering, Stem cell treatment, Bioinformatics and Computational biology, Bio Ethics and Patent Rights. Reputed speakers at the Cell Science-2014, an international medical conference 2014, including Stewart Sell of University of Albany, USA, Sudhakar Akul Yakkanti, SRI International, USA, Jimmy Thomas Efrid, Brody School of Medicine, USA and Diana Anderson, University of Bradford, UK are going to share their experiences in this field. OMICS Group International, an open access publisher that publishes 300 online, peer reviewed science journals in the fields of Clinical, Medical, Engineering and technological, Pharmaceutical and Management fields also organizes more than 100 international science conferences and events across the globe. With the help of more than 150 scientific associations with the like-minded organization, OMICS Group is contributing for … Continue reading →